Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology

Rapid and continuing advances in biomarker testing are not being matched by take-up in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. This paper sets out the potential of biomarker testing, the unfolding precision and range of possible diagnosis and prediction, and the many obstacles to adoption. It offers case studies of biomarker testing in breast, ovarian, prostate, lung, thyroid and colon cancers, and derives specific lessons as to the potential and actual use of each of them. It also draws lessons about how to improve access and alignment, and to remedy the data deficiencies that impede development. And it suggests solutions to outstanding issues – notably including funding and the tangled web of obtaining reimbursement or equivalent coverage that Europe’s fragmented health system implies. It urges a European evolution towards an initial minimum testing scenario, which would guarantee universal access to a suite of biomarker tests for the currently most common conditions, and, further into the future, to an optimum testing scenario in which a much wider range of biomarker tests would be introduced and become part of a more sophisticated health system articulated around personalised medicine. For exploiting genomics to the full, it argues the need for a new policy framework for Europe. Biomarker testing is not an issue that can be treated in isolation, since the purpose of testing is to improve health. Its use is therefore always closely linked to specific health challenges and needs to be viewed in the broader policy context in the EU and more widely. The paper is the result of extensive engagement with experts and decision makers to develop the framework, and consequently represents a wide consensus of views on how healthcare systems should respond from push and pull factors at local, national and cross-border and EU level. It contains strong views and clear recommendations springing from the convictions of patients, clinicians, academics, medicines authorities, HTA bodies, payers, the diagnostic, pharmaceutical and ICT industries, and national policy makers. Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Denis Horgan [verfasserIn] Gennaro Ciliberto [verfasserIn] Pierfranco Conte [verfasserIn] David Baldwin [verfasserIn] Luis Seijo [verfasserIn] Luis M. Montuenga [verfasserIn] Luis Paz-Ares [verfasserIn] Marina Garassino [verfasserIn] Frederique Penault-Llorca [verfasserIn] Fabrizia Galli [verfasserIn] Isabelle Ray-Coquard [verfasserIn] Denis Querleu [verfasserIn] Ettore Capoluongo [verfasserIn] Susana Banerjee [verfasserIn] Peter Riegman [verfasserIn] Keith Kerr [verfasserIn] Benjamin Horbach [verfasserIn] Reinhard Büttner [verfasserIn] Hein Van Poppel [verfasserIn] Anders Bjartell [verfasserIn] Giovanni Codacci-Pisanelli [verfasserIn] Benedikt Westphalen [verfasserIn] Fabien Calvo [verfasserIn] Jasmina Koeva-Balabanova [verfasserIn] Stephen Hall [verfasserIn] Angelo Paradiso [verfasserIn] Dipak Kalra [verfasserIn] Christa Cobbaert [verfasserIn] Rocio Varea Menendez [verfasserIn] Zorana Maravic [verfasserIn] Vassiliki Fotaki [verfasserIn] Jaafar Bennouna [verfasserIn] Estelle Cauchin [verfasserIn] Nuria Malats [verfasserIn] Iñaki Gutiérrez-Ibarluzea [verfasserIn] Benjamin Gannon [verfasserIn] Ken Mastris [verfasserIn] Chiara Bernini [verfasserIn] William Gallagher [verfasserIn] Simonetta Buglioni [verfasserIn] Alastair Kent [verfasserIn] Elisabetta Munzone [verfasserIn] Ivica Belina [verfasserIn] Jan Van Meerbeeck [verfasserIn] Michael Duffy [verfasserIn] Elżbieta Sarnowska [verfasserIn] Beata Jagielska [verfasserIn] Sarah Mee [verfasserIn] Giuseppe Curigliano [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2020

Schlagwörter:	biomarkers cancer plan companion diagnostics comprehensive genomic profiling diagnostic tests million european genome molecular diagnostics personalised healthcare public health reimbursement challenges

Übergeordnetes Werk:	In: Biomedicine Hub - Karger Publishers, 2017, 5(2020), 3, Seite 1
Übergeordnetes Werk:	volume:5 ; year:2020 ; number:3 ; pages:1

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1159/000511209

Katalog-ID:	DOAJ008577161

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ008577161
003	DE-627
005	20230310012159.0
007	cr uuu---uuuuu
008	230225s2020 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1159/000511209 \|2 doi
035			\|a (DE-627)DOAJ008577161
035			\|a (DE-599)DOAJ23c9748ba2f5428dbcd608ea1ef409ad
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a R5-920
100	0		\|a Denis Horgan \|e verfasserin \|4 aut
245	1	0	\|a Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Rapid and continuing advances in biomarker testing are not being matched by take-up in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. This paper sets out the potential of biomarker testing, the unfolding precision and range of possible diagnosis and prediction, and the many obstacles to adoption. It offers case studies of biomarker testing in breast, ovarian, prostate, lung, thyroid and colon cancers, and derives specific lessons as to the potential and actual use of each of them. It also draws lessons about how to improve access and alignment, and to remedy the data deficiencies that impede development. And it suggests solutions to outstanding issues – notably including funding and the tangled web of obtaining reimbursement or equivalent coverage that Europe’s fragmented health system implies. It urges a European evolution towards an initial minimum testing scenario, which would guarantee universal access to a suite of biomarker tests for the currently most common conditions, and, further into the future, to an optimum testing scenario in which a much wider range of biomarker tests would be introduced and become part of a more sophisticated health system articulated around personalised medicine. For exploiting genomics to the full, it argues the need for a new policy framework for Europe. Biomarker testing is not an issue that can be treated in isolation, since the purpose of testing is to improve health. Its use is therefore always closely linked to specific health challenges and needs to be viewed in the broader policy context in the EU and more widely. The paper is the result of extensive engagement with experts and decision makers to develop the framework, and consequently represents a wide consensus of views on how healthcare systems should respond from push and pull factors at local, national and cross-border and EU level. It contains strong views and clear recommendations springing from the convictions of patients, clinicians, academics, medicines authorities, HTA bodies, payers, the diagnostic, pharmaceutical and ICT industries, and national policy makers.
650		4	\|a biomarkers
650		4	\|a cancer plan
650		4	\|a companion diagnostics
650		4	\|a comprehensive genomic profiling
650		4	\|a diagnostic tests
650		4	\|a million european genome
650		4	\|a molecular diagnostics
650		4	\|a personalised healthcare
650		4	\|a public health
650		4	\|a reimbursement challenges
653		0	\|a Medicine (General)
700	0		\|a Gennaro Ciliberto \|e verfasserin \|4 aut
700	0		\|a Pierfranco Conte \|e verfasserin \|4 aut
700	0		\|a David Baldwin \|e verfasserin \|4 aut
700	0		\|a Luis Seijo \|e verfasserin \|4 aut
700	0		\|a Luis M. Montuenga \|e verfasserin \|4 aut
700	0		\|a Luis Paz-Ares \|e verfasserin \|4 aut
700	0		\|a Marina Garassino \|e verfasserin \|4 aut
700	0		\|a Frederique Penault-Llorca \|e verfasserin \|4 aut
700	0		\|a Fabrizia Galli \|e verfasserin \|4 aut
700	0		\|a Isabelle Ray-Coquard \|e verfasserin \|4 aut
700	0		\|a Denis Querleu \|e verfasserin \|4 aut
700	0		\|a Ettore Capoluongo \|e verfasserin \|4 aut
700	0		\|a Susana Banerjee \|e verfasserin \|4 aut
700	0		\|a Peter Riegman \|e verfasserin \|4 aut
700	0		\|a Keith Kerr \|e verfasserin \|4 aut
700	0		\|a Benjamin Horbach \|e verfasserin \|4 aut
700	0		\|a Reinhard Büttner \|e verfasserin \|4 aut
700	0		\|a Hein Van Poppel \|e verfasserin \|4 aut
700	0		\|a Anders Bjartell \|e verfasserin \|4 aut
700	0		\|a Giovanni Codacci-Pisanelli \|e verfasserin \|4 aut
700	0		\|a Benedikt Westphalen \|e verfasserin \|4 aut
700	0		\|a Fabien Calvo \|e verfasserin \|4 aut
700	0		\|a Jasmina Koeva-Balabanova \|e verfasserin \|4 aut
700	0		\|a Stephen Hall \|e verfasserin \|4 aut
700	0		\|a Angelo Paradiso \|e verfasserin \|4 aut
700	0		\|a Dipak Kalra \|e verfasserin \|4 aut
700	0		\|a Christa Cobbaert \|e verfasserin \|4 aut
700	0		\|a Rocio Varea Menendez \|e verfasserin \|4 aut
700	0		\|a Zorana Maravic \|e verfasserin \|4 aut
700	0		\|a Vassiliki Fotaki \|e verfasserin \|4 aut
700	0		\|a Jaafar Bennouna \|e verfasserin \|4 aut
700	0		\|a Estelle Cauchin \|e verfasserin \|4 aut
700	0		\|a Nuria Malats \|e verfasserin \|4 aut
700	0		\|a Iñaki Gutiérrez-Ibarluzea \|e verfasserin \|4 aut
700	0		\|a Benjamin Gannon \|e verfasserin \|4 aut
700	0		\|a Ken Mastris \|e verfasserin \|4 aut
700	0		\|a Chiara Bernini \|e verfasserin \|4 aut
700	0		\|a William Gallagher \|e verfasserin \|4 aut
700	0		\|a Simonetta Buglioni \|e verfasserin \|4 aut
700	0		\|a Alastair Kent \|e verfasserin \|4 aut
700	0		\|a Elisabetta Munzone \|e verfasserin \|4 aut
700	0		\|a Ivica Belina \|e verfasserin \|4 aut
700	0		\|a Jan Van Meerbeeck \|e verfasserin \|4 aut
700	0		\|a Michael Duffy \|e verfasserin \|4 aut
700	0		\|a Elżbieta Sarnowska \|e verfasserin \|4 aut
700	0		\|a Beata Jagielska \|e verfasserin \|4 aut
700	0		\|a Sarah Mee \|e verfasserin \|4 aut
700	0		\|a Giuseppe Curigliano \|e verfasserin \|4 aut
773	0	8	\|i In \|t Biomedicine Hub \|d Karger Publishers, 2017 \|g 5(2020), 3, Seite 1 \|w (DE-627)859340082 \|w (DE-600)2855840-6 \|x 22966870 \|7 nnns
773	1	8	\|g volume:5 \|g year:2020 \|g number:3 \|g pages:1
856	4	0	\|u https://doi.org/10.1159/000511209 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/23c9748ba2f5428dbcd608ea1ef409ad \|z kostenfrei
856	4	0	\|u https://www.karger.com/Article/FullText/511209 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2296-6870 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2018
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 5 \|j 2020 \|e 3 \|h 1

Indexfelder

author_variant	d h dh g c gc p c pc d b db l s ls l m lm l p a lpa m g mg f p l fpl f g fg i r c irc d q dq e c ec s b sb p r pr k k kk b h bh r b rb h v hv a b ab g c p gcp b w bw f c fc j k b jkb s h sh a p ap d k dk c c cc r v rv z m zm v f vf j b jb e c ec n m nm i g i igi b g bg k m km c b cb w g wg s b sb a k ak e m em i b ib j v jv m d md e s es b j bj s m sm g c gc
matchkey_str	article:22966870:2020----::rnigraeacrcterpselhaeytmtenxlieptnilf
hierarchy_sort_str	2020
callnumber-subject-code	R
publishDate	2020
allfields	10.1159/000511209 doi (DE-627)DOAJ008577161 (DE-599)DOAJ23c9748ba2f5428dbcd608ea1ef409ad DE-627 ger DE-627 rakwb eng R5-920 Denis Horgan verfasserin aut Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Rapid and continuing advances in biomarker testing are not being matched by take-up in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. This paper sets out the potential of biomarker testing, the unfolding precision and range of possible diagnosis and prediction, and the many obstacles to adoption. It offers case studies of biomarker testing in breast, ovarian, prostate, lung, thyroid and colon cancers, and derives specific lessons as to the potential and actual use of each of them. It also draws lessons about how to improve access and alignment, and to remedy the data deficiencies that impede development. And it suggests solutions to outstanding issues – notably including funding and the tangled web of obtaining reimbursement or equivalent coverage that Europe’s fragmented health system implies. It urges a European evolution towards an initial minimum testing scenario, which would guarantee universal access to a suite of biomarker tests for the currently most common conditions, and, further into the future, to an optimum testing scenario in which a much wider range of biomarker tests would be introduced and become part of a more sophisticated health system articulated around personalised medicine. For exploiting genomics to the full, it argues the need for a new policy framework for Europe. Biomarker testing is not an issue that can be treated in isolation, since the purpose of testing is to improve health. Its use is therefore always closely linked to specific health challenges and needs to be viewed in the broader policy context in the EU and more widely. The paper is the result of extensive engagement with experts and decision makers to develop the framework, and consequently represents a wide consensus of views on how healthcare systems should respond from push and pull factors at local, national and cross-border and EU level. It contains strong views and clear recommendations springing from the convictions of patients, clinicians, academics, medicines authorities, HTA bodies, payers, the diagnostic, pharmaceutical and ICT industries, and national policy makers. biomarkers cancer plan companion diagnostics comprehensive genomic profiling diagnostic tests million european genome molecular diagnostics personalised healthcare public health reimbursement challenges Medicine (General) Gennaro Ciliberto verfasserin aut Pierfranco Conte verfasserin aut David Baldwin verfasserin aut Luis Seijo verfasserin aut Luis M. Montuenga verfasserin aut Luis Paz-Ares verfasserin aut Marina Garassino verfasserin aut Frederique Penault-Llorca verfasserin aut Fabrizia Galli verfasserin aut Isabelle Ray-Coquard verfasserin aut Denis Querleu verfasserin aut Ettore Capoluongo verfasserin aut Susana Banerjee verfasserin aut Peter Riegman verfasserin aut Keith Kerr verfasserin aut Benjamin Horbach verfasserin aut Reinhard Büttner verfasserin aut Hein Van Poppel verfasserin aut Anders Bjartell verfasserin aut Giovanni Codacci-Pisanelli verfasserin aut Benedikt Westphalen verfasserin aut Fabien Calvo verfasserin aut Jasmina Koeva-Balabanova verfasserin aut Stephen Hall verfasserin aut Angelo Paradiso verfasserin aut Dipak Kalra verfasserin aut Christa Cobbaert verfasserin aut Rocio Varea Menendez verfasserin aut Zorana Maravic verfasserin aut Vassiliki Fotaki verfasserin aut Jaafar Bennouna verfasserin aut Estelle Cauchin verfasserin aut Nuria Malats verfasserin aut Iñaki Gutiérrez-Ibarluzea verfasserin aut Benjamin Gannon verfasserin aut Ken Mastris verfasserin aut Chiara Bernini verfasserin aut William Gallagher verfasserin aut Simonetta Buglioni verfasserin aut Alastair Kent verfasserin aut Elisabetta Munzone verfasserin aut Ivica Belina verfasserin aut Jan Van Meerbeeck verfasserin aut Michael Duffy verfasserin aut Elżbieta Sarnowska verfasserin aut Beata Jagielska verfasserin aut Sarah Mee verfasserin aut Giuseppe Curigliano verfasserin aut In Biomedicine Hub Karger Publishers, 2017 5(2020), 3, Seite 1 (DE-627)859340082 (DE-600)2855840-6 22966870 nnns volume:5 year:2020 number:3 pages:1 https://doi.org/10.1159/000511209 kostenfrei https://doaj.org/article/23c9748ba2f5428dbcd608ea1ef409ad kostenfrei https://www.karger.com/Article/FullText/511209 kostenfrei https://doaj.org/toc/2296-6870 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2018 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 5 2020 3 1
spelling	10.1159/000511209 doi (DE-627)DOAJ008577161 (DE-599)DOAJ23c9748ba2f5428dbcd608ea1ef409ad DE-627 ger DE-627 rakwb eng R5-920 Denis Horgan verfasserin aut Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Rapid and continuing advances in biomarker testing are not being matched by take-up in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. This paper sets out the potential of biomarker testing, the unfolding precision and range of possible diagnosis and prediction, and the many obstacles to adoption. It offers case studies of biomarker testing in breast, ovarian, prostate, lung, thyroid and colon cancers, and derives specific lessons as to the potential and actual use of each of them. It also draws lessons about how to improve access and alignment, and to remedy the data deficiencies that impede development. And it suggests solutions to outstanding issues – notably including funding and the tangled web of obtaining reimbursement or equivalent coverage that Europe’s fragmented health system implies. It urges a European evolution towards an initial minimum testing scenario, which would guarantee universal access to a suite of biomarker tests for the currently most common conditions, and, further into the future, to an optimum testing scenario in which a much wider range of biomarker tests would be introduced and become part of a more sophisticated health system articulated around personalised medicine. For exploiting genomics to the full, it argues the need for a new policy framework for Europe. Biomarker testing is not an issue that can be treated in isolation, since the purpose of testing is to improve health. Its use is therefore always closely linked to specific health challenges and needs to be viewed in the broader policy context in the EU and more widely. The paper is the result of extensive engagement with experts and decision makers to develop the framework, and consequently represents a wide consensus of views on how healthcare systems should respond from push and pull factors at local, national and cross-border and EU level. It contains strong views and clear recommendations springing from the convictions of patients, clinicians, academics, medicines authorities, HTA bodies, payers, the diagnostic, pharmaceutical and ICT industries, and national policy makers. biomarkers cancer plan companion diagnostics comprehensive genomic profiling diagnostic tests million european genome molecular diagnostics personalised healthcare public health reimbursement challenges Medicine (General) Gennaro Ciliberto verfasserin aut Pierfranco Conte verfasserin aut David Baldwin verfasserin aut Luis Seijo verfasserin aut Luis M. Montuenga verfasserin aut Luis Paz-Ares verfasserin aut Marina Garassino verfasserin aut Frederique Penault-Llorca verfasserin aut Fabrizia Galli verfasserin aut Isabelle Ray-Coquard verfasserin aut Denis Querleu verfasserin aut Ettore Capoluongo verfasserin aut Susana Banerjee verfasserin aut Peter Riegman verfasserin aut Keith Kerr verfasserin aut Benjamin Horbach verfasserin aut Reinhard Büttner verfasserin aut Hein Van Poppel verfasserin aut Anders Bjartell verfasserin aut Giovanni Codacci-Pisanelli verfasserin aut Benedikt Westphalen verfasserin aut Fabien Calvo verfasserin aut Jasmina Koeva-Balabanova verfasserin aut Stephen Hall verfasserin aut Angelo Paradiso verfasserin aut Dipak Kalra verfasserin aut Christa Cobbaert verfasserin aut Rocio Varea Menendez verfasserin aut Zorana Maravic verfasserin aut Vassiliki Fotaki verfasserin aut Jaafar Bennouna verfasserin aut Estelle Cauchin verfasserin aut Nuria Malats verfasserin aut Iñaki Gutiérrez-Ibarluzea verfasserin aut Benjamin Gannon verfasserin aut Ken Mastris verfasserin aut Chiara Bernini verfasserin aut William Gallagher verfasserin aut Simonetta Buglioni verfasserin aut Alastair Kent verfasserin aut Elisabetta Munzone verfasserin aut Ivica Belina verfasserin aut Jan Van Meerbeeck verfasserin aut Michael Duffy verfasserin aut Elżbieta Sarnowska verfasserin aut Beata Jagielska verfasserin aut Sarah Mee verfasserin aut Giuseppe Curigliano verfasserin aut In Biomedicine Hub Karger Publishers, 2017 5(2020), 3, Seite 1 (DE-627)859340082 (DE-600)2855840-6 22966870 nnns volume:5 year:2020 number:3 pages:1 https://doi.org/10.1159/000511209 kostenfrei https://doaj.org/article/23c9748ba2f5428dbcd608ea1ef409ad kostenfrei https://www.karger.com/Article/FullText/511209 kostenfrei https://doaj.org/toc/2296-6870 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2018 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 5 2020 3 1
allfields_unstemmed	10.1159/000511209 doi (DE-627)DOAJ008577161 (DE-599)DOAJ23c9748ba2f5428dbcd608ea1ef409ad DE-627 ger DE-627 rakwb eng R5-920 Denis Horgan verfasserin aut Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Rapid and continuing advances in biomarker testing are not being matched by take-up in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. This paper sets out the potential of biomarker testing, the unfolding precision and range of possible diagnosis and prediction, and the many obstacles to adoption. It offers case studies of biomarker testing in breast, ovarian, prostate, lung, thyroid and colon cancers, and derives specific lessons as to the potential and actual use of each of them. It also draws lessons about how to improve access and alignment, and to remedy the data deficiencies that impede development. And it suggests solutions to outstanding issues – notably including funding and the tangled web of obtaining reimbursement or equivalent coverage that Europe’s fragmented health system implies. It urges a European evolution towards an initial minimum testing scenario, which would guarantee universal access to a suite of biomarker tests for the currently most common conditions, and, further into the future, to an optimum testing scenario in which a much wider range of biomarker tests would be introduced and become part of a more sophisticated health system articulated around personalised medicine. For exploiting genomics to the full, it argues the need for a new policy framework for Europe. Biomarker testing is not an issue that can be treated in isolation, since the purpose of testing is to improve health. Its use is therefore always closely linked to specific health challenges and needs to be viewed in the broader policy context in the EU and more widely. The paper is the result of extensive engagement with experts and decision makers to develop the framework, and consequently represents a wide consensus of views on how healthcare systems should respond from push and pull factors at local, national and cross-border and EU level. It contains strong views and clear recommendations springing from the convictions of patients, clinicians, academics, medicines authorities, HTA bodies, payers, the diagnostic, pharmaceutical and ICT industries, and national policy makers. biomarkers cancer plan companion diagnostics comprehensive genomic profiling diagnostic tests million european genome molecular diagnostics personalised healthcare public health reimbursement challenges Medicine (General) Gennaro Ciliberto verfasserin aut Pierfranco Conte verfasserin aut David Baldwin verfasserin aut Luis Seijo verfasserin aut Luis M. Montuenga verfasserin aut Luis Paz-Ares verfasserin aut Marina Garassino verfasserin aut Frederique Penault-Llorca verfasserin aut Fabrizia Galli verfasserin aut Isabelle Ray-Coquard verfasserin aut Denis Querleu verfasserin aut Ettore Capoluongo verfasserin aut Susana Banerjee verfasserin aut Peter Riegman verfasserin aut Keith Kerr verfasserin aut Benjamin Horbach verfasserin aut Reinhard Büttner verfasserin aut Hein Van Poppel verfasserin aut Anders Bjartell verfasserin aut Giovanni Codacci-Pisanelli verfasserin aut Benedikt Westphalen verfasserin aut Fabien Calvo verfasserin aut Jasmina Koeva-Balabanova verfasserin aut Stephen Hall verfasserin aut Angelo Paradiso verfasserin aut Dipak Kalra verfasserin aut Christa Cobbaert verfasserin aut Rocio Varea Menendez verfasserin aut Zorana Maravic verfasserin aut Vassiliki Fotaki verfasserin aut Jaafar Bennouna verfasserin aut Estelle Cauchin verfasserin aut Nuria Malats verfasserin aut Iñaki Gutiérrez-Ibarluzea verfasserin aut Benjamin Gannon verfasserin aut Ken Mastris verfasserin aut Chiara Bernini verfasserin aut William Gallagher verfasserin aut Simonetta Buglioni verfasserin aut Alastair Kent verfasserin aut Elisabetta Munzone verfasserin aut Ivica Belina verfasserin aut Jan Van Meerbeeck verfasserin aut Michael Duffy verfasserin aut Elżbieta Sarnowska verfasserin aut Beata Jagielska verfasserin aut Sarah Mee verfasserin aut Giuseppe Curigliano verfasserin aut In Biomedicine Hub Karger Publishers, 2017 5(2020), 3, Seite 1 (DE-627)859340082 (DE-600)2855840-6 22966870 nnns volume:5 year:2020 number:3 pages:1 https://doi.org/10.1159/000511209 kostenfrei https://doaj.org/article/23c9748ba2f5428dbcd608ea1ef409ad kostenfrei https://www.karger.com/Article/FullText/511209 kostenfrei https://doaj.org/toc/2296-6870 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2018 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 5 2020 3 1
allfieldsGer	10.1159/000511209 doi (DE-627)DOAJ008577161 (DE-599)DOAJ23c9748ba2f5428dbcd608ea1ef409ad DE-627 ger DE-627 rakwb eng R5-920 Denis Horgan verfasserin aut Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Rapid and continuing advances in biomarker testing are not being matched by take-up in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. This paper sets out the potential of biomarker testing, the unfolding precision and range of possible diagnosis and prediction, and the many obstacles to adoption. It offers case studies of biomarker testing in breast, ovarian, prostate, lung, thyroid and colon cancers, and derives specific lessons as to the potential and actual use of each of them. It also draws lessons about how to improve access and alignment, and to remedy the data deficiencies that impede development. And it suggests solutions to outstanding issues – notably including funding and the tangled web of obtaining reimbursement or equivalent coverage that Europe’s fragmented health system implies. It urges a European evolution towards an initial minimum testing scenario, which would guarantee universal access to a suite of biomarker tests for the currently most common conditions, and, further into the future, to an optimum testing scenario in which a much wider range of biomarker tests would be introduced and become part of a more sophisticated health system articulated around personalised medicine. For exploiting genomics to the full, it argues the need for a new policy framework for Europe. Biomarker testing is not an issue that can be treated in isolation, since the purpose of testing is to improve health. Its use is therefore always closely linked to specific health challenges and needs to be viewed in the broader policy context in the EU and more widely. The paper is the result of extensive engagement with experts and decision makers to develop the framework, and consequently represents a wide consensus of views on how healthcare systems should respond from push and pull factors at local, national and cross-border and EU level. It contains strong views and clear recommendations springing from the convictions of patients, clinicians, academics, medicines authorities, HTA bodies, payers, the diagnostic, pharmaceutical and ICT industries, and national policy makers. biomarkers cancer plan companion diagnostics comprehensive genomic profiling diagnostic tests million european genome molecular diagnostics personalised healthcare public health reimbursement challenges Medicine (General) Gennaro Ciliberto verfasserin aut Pierfranco Conte verfasserin aut David Baldwin verfasserin aut Luis Seijo verfasserin aut Luis M. Montuenga verfasserin aut Luis Paz-Ares verfasserin aut Marina Garassino verfasserin aut Frederique Penault-Llorca verfasserin aut Fabrizia Galli verfasserin aut Isabelle Ray-Coquard verfasserin aut Denis Querleu verfasserin aut Ettore Capoluongo verfasserin aut Susana Banerjee verfasserin aut Peter Riegman verfasserin aut Keith Kerr verfasserin aut Benjamin Horbach verfasserin aut Reinhard Büttner verfasserin aut Hein Van Poppel verfasserin aut Anders Bjartell verfasserin aut Giovanni Codacci-Pisanelli verfasserin aut Benedikt Westphalen verfasserin aut Fabien Calvo verfasserin aut Jasmina Koeva-Balabanova verfasserin aut Stephen Hall verfasserin aut Angelo Paradiso verfasserin aut Dipak Kalra verfasserin aut Christa Cobbaert verfasserin aut Rocio Varea Menendez verfasserin aut Zorana Maravic verfasserin aut Vassiliki Fotaki verfasserin aut Jaafar Bennouna verfasserin aut Estelle Cauchin verfasserin aut Nuria Malats verfasserin aut Iñaki Gutiérrez-Ibarluzea verfasserin aut Benjamin Gannon verfasserin aut Ken Mastris verfasserin aut Chiara Bernini verfasserin aut William Gallagher verfasserin aut Simonetta Buglioni verfasserin aut Alastair Kent verfasserin aut Elisabetta Munzone verfasserin aut Ivica Belina verfasserin aut Jan Van Meerbeeck verfasserin aut Michael Duffy verfasserin aut Elżbieta Sarnowska verfasserin aut Beata Jagielska verfasserin aut Sarah Mee verfasserin aut Giuseppe Curigliano verfasserin aut In Biomedicine Hub Karger Publishers, 2017 5(2020), 3, Seite 1 (DE-627)859340082 (DE-600)2855840-6 22966870 nnns volume:5 year:2020 number:3 pages:1 https://doi.org/10.1159/000511209 kostenfrei https://doaj.org/article/23c9748ba2f5428dbcd608ea1ef409ad kostenfrei https://www.karger.com/Article/FullText/511209 kostenfrei https://doaj.org/toc/2296-6870 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2018 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 5 2020 3 1
allfieldsSound	10.1159/000511209 doi (DE-627)DOAJ008577161 (DE-599)DOAJ23c9748ba2f5428dbcd608ea1ef409ad DE-627 ger DE-627 rakwb eng R5-920 Denis Horgan verfasserin aut Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Rapid and continuing advances in biomarker testing are not being matched by take-up in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. This paper sets out the potential of biomarker testing, the unfolding precision and range of possible diagnosis and prediction, and the many obstacles to adoption. It offers case studies of biomarker testing in breast, ovarian, prostate, lung, thyroid and colon cancers, and derives specific lessons as to the potential and actual use of each of them. It also draws lessons about how to improve access and alignment, and to remedy the data deficiencies that impede development. And it suggests solutions to outstanding issues – notably including funding and the tangled web of obtaining reimbursement or equivalent coverage that Europe’s fragmented health system implies. It urges a European evolution towards an initial minimum testing scenario, which would guarantee universal access to a suite of biomarker tests for the currently most common conditions, and, further into the future, to an optimum testing scenario in which a much wider range of biomarker tests would be introduced and become part of a more sophisticated health system articulated around personalised medicine. For exploiting genomics to the full, it argues the need for a new policy framework for Europe. Biomarker testing is not an issue that can be treated in isolation, since the purpose of testing is to improve health. Its use is therefore always closely linked to specific health challenges and needs to be viewed in the broader policy context in the EU and more widely. The paper is the result of extensive engagement with experts and decision makers to develop the framework, and consequently represents a wide consensus of views on how healthcare systems should respond from push and pull factors at local, national and cross-border and EU level. It contains strong views and clear recommendations springing from the convictions of patients, clinicians, academics, medicines authorities, HTA bodies, payers, the diagnostic, pharmaceutical and ICT industries, and national policy makers. biomarkers cancer plan companion diagnostics comprehensive genomic profiling diagnostic tests million european genome molecular diagnostics personalised healthcare public health reimbursement challenges Medicine (General) Gennaro Ciliberto verfasserin aut Pierfranco Conte verfasserin aut David Baldwin verfasserin aut Luis Seijo verfasserin aut Luis M. Montuenga verfasserin aut Luis Paz-Ares verfasserin aut Marina Garassino verfasserin aut Frederique Penault-Llorca verfasserin aut Fabrizia Galli verfasserin aut Isabelle Ray-Coquard verfasserin aut Denis Querleu verfasserin aut Ettore Capoluongo verfasserin aut Susana Banerjee verfasserin aut Peter Riegman verfasserin aut Keith Kerr verfasserin aut Benjamin Horbach verfasserin aut Reinhard Büttner verfasserin aut Hein Van Poppel verfasserin aut Anders Bjartell verfasserin aut Giovanni Codacci-Pisanelli verfasserin aut Benedikt Westphalen verfasserin aut Fabien Calvo verfasserin aut Jasmina Koeva-Balabanova verfasserin aut Stephen Hall verfasserin aut Angelo Paradiso verfasserin aut Dipak Kalra verfasserin aut Christa Cobbaert verfasserin aut Rocio Varea Menendez verfasserin aut Zorana Maravic verfasserin aut Vassiliki Fotaki verfasserin aut Jaafar Bennouna verfasserin aut Estelle Cauchin verfasserin aut Nuria Malats verfasserin aut Iñaki Gutiérrez-Ibarluzea verfasserin aut Benjamin Gannon verfasserin aut Ken Mastris verfasserin aut Chiara Bernini verfasserin aut William Gallagher verfasserin aut Simonetta Buglioni verfasserin aut Alastair Kent verfasserin aut Elisabetta Munzone verfasserin aut Ivica Belina verfasserin aut Jan Van Meerbeeck verfasserin aut Michael Duffy verfasserin aut Elżbieta Sarnowska verfasserin aut Beata Jagielska verfasserin aut Sarah Mee verfasserin aut Giuseppe Curigliano verfasserin aut In Biomedicine Hub Karger Publishers, 2017 5(2020), 3, Seite 1 (DE-627)859340082 (DE-600)2855840-6 22966870 nnns volume:5 year:2020 number:3 pages:1 https://doi.org/10.1159/000511209 kostenfrei https://doaj.org/article/23c9748ba2f5428dbcd608ea1ef409ad kostenfrei https://www.karger.com/Article/FullText/511209 kostenfrei https://doaj.org/toc/2296-6870 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2018 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 5 2020 3 1
language	English
source	In Biomedicine Hub 5(2020), 3, Seite 1 volume:5 year:2020 number:3 pages:1
sourceStr	In Biomedicine Hub 5(2020), 3, Seite 1 volume:5 year:2020 number:3 pages:1
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	biomarkers cancer plan companion diagnostics comprehensive genomic profiling diagnostic tests million european genome molecular diagnostics personalised healthcare public health reimbursement challenges Medicine (General)
isfreeaccess_bool	true
container_title	Biomedicine Hub
authorswithroles_txt_mv	Denis Horgan @@aut@@ Gennaro Ciliberto @@aut@@ Pierfranco Conte @@aut@@ David Baldwin @@aut@@ Luis Seijo @@aut@@ Luis M. Montuenga @@aut@@ Luis Paz-Ares @@aut@@ Marina Garassino @@aut@@ Frederique Penault-Llorca @@aut@@ Fabrizia Galli @@aut@@ Isabelle Ray-Coquard @@aut@@ Denis Querleu @@aut@@ Ettore Capoluongo @@aut@@ Susana Banerjee @@aut@@ Peter Riegman @@aut@@ Keith Kerr @@aut@@ Benjamin Horbach @@aut@@ Reinhard Büttner @@aut@@ Hein Van Poppel @@aut@@ Anders Bjartell @@aut@@ Giovanni Codacci-Pisanelli @@aut@@ Benedikt Westphalen @@aut@@ Fabien Calvo @@aut@@ Jasmina Koeva-Balabanova @@aut@@ Stephen Hall @@aut@@ Angelo Paradiso @@aut@@ Dipak Kalra @@aut@@ Christa Cobbaert @@aut@@ Rocio Varea Menendez @@aut@@ Zorana Maravic @@aut@@ Vassiliki Fotaki @@aut@@ Jaafar Bennouna @@aut@@ Estelle Cauchin @@aut@@ Nuria Malats @@aut@@ Iñaki Gutiérrez-Ibarluzea @@aut@@ Benjamin Gannon @@aut@@ Ken Mastris @@aut@@ Chiara Bernini @@aut@@ William Gallagher @@aut@@ Simonetta Buglioni @@aut@@ Alastair Kent @@aut@@ Elisabetta Munzone @@aut@@ Ivica Belina @@aut@@ Jan Van Meerbeeck @@aut@@ Michael Duffy @@aut@@ Elżbieta Sarnowska @@aut@@ Beata Jagielska @@aut@@ Sarah Mee @@aut@@ Giuseppe Curigliano @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	859340082
id	DOAJ008577161
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ008577161</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310012159.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1159/000511209</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ008577161</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ23c9748ba2f5428dbcd608ea1ef409ad</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Denis Horgan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Rapid and continuing advances in biomarker testing are not being matched by take-up in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. This paper sets out the potential of biomarker testing, the unfolding precision and range of possible diagnosis and prediction, and the many obstacles to adoption. It offers case studies of biomarker testing in breast, ovarian, prostate, lung, thyroid and colon cancers, and derives specific lessons as to the potential and actual use of each of them. It also draws lessons about how to improve access and alignment, and to remedy the data deficiencies that impede development. And it suggests solutions to outstanding issues – notably including funding and the tangled web of obtaining reimbursement or equivalent coverage that Europe’s fragmented health system implies. It urges a European evolution towards an initial minimum testing scenario, which would guarantee universal access to a suite of biomarker tests for the currently most common conditions, and, further into the future, to an optimum testing scenario in which a much wider range of biomarker tests would be introduced and become part of a more sophisticated health system articulated around personalised medicine. For exploiting genomics to the full, it argues the need for a new policy framework for Europe. Biomarker testing is not an issue that can be treated in isolation, since the purpose of testing is to improve health. Its use is therefore always closely linked to specific health challenges and needs to be viewed in the broader policy context in the EU and more widely. The paper is the result of extensive engagement with experts and decision makers to develop the framework, and consequently represents a wide consensus of views on how healthcare systems should respond from push and pull factors at local, national and cross-border and EU level. It contains strong views and clear recommendations springing from the convictions of patients, clinicians, academics, medicines authorities, HTA bodies, payers, the diagnostic, pharmaceutical and ICT industries, and national policy makers.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">biomarkers</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cancer plan</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">companion diagnostics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">comprehensive genomic profiling</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">diagnostic tests</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">million european genome</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">molecular diagnostics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">personalised healthcare</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">public health</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">reimbursement challenges</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gennaro Ciliberto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pierfranco Conte</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">David Baldwin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luis Seijo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luis M. Montuenga</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luis Paz-Ares</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marina Garassino</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Frederique Penault-Llorca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fabrizia Galli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Isabelle Ray-Coquard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Denis Querleu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ettore Capoluongo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Susana Banerjee</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Peter Riegman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Keith Kerr</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Benjamin Horbach</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Reinhard Büttner</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hein Van Poppel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anders Bjartell</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giovanni Codacci-Pisanelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Benedikt Westphalen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fabien Calvo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jasmina Koeva-Balabanova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stephen Hall</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Angelo Paradiso</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dipak Kalra</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Christa Cobbaert</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rocio Varea Menendez</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zorana Maravic</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vassiliki Fotaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jaafar Bennouna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Estelle Cauchin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nuria Malats</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Iñaki Gutiérrez-Ibarluzea</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Benjamin Gannon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ken Mastris</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chiara Bernini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">William Gallagher</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Simonetta Buglioni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alastair Kent</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elisabetta Munzone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ivica Belina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jan Van Meerbeeck</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michael Duffy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elżbieta Sarnowska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Beata Jagielska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sarah Mee</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giuseppe Curigliano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Biomedicine Hub</subfield><subfield code="d">Karger Publishers, 2017</subfield><subfield code="g">5(2020), 3, Seite 1</subfield><subfield code="w">(DE-627)859340082</subfield><subfield code="w">(DE-600)2855840-6</subfield><subfield code="x">22966870</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:5</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:1</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1159/000511209</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/23c9748ba2f5428dbcd608ea1ef409ad</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.karger.com/Article/FullText/511209</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2296-6870</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2018</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">5</subfield><subfield code="j">2020</subfield><subfield code="e">3</subfield><subfield code="h">1</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Denis Horgan
spellingShingle	Denis Horgan misc R5-920 misc biomarkers misc cancer plan misc companion diagnostics misc comprehensive genomic profiling misc diagnostic tests misc million european genome misc molecular diagnostics misc personalised healthcare misc public health misc reimbursement challenges misc Medicine (General) Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology
authorStr	Denis Horgan
ppnlink_with_tag_str_mv	@@773@@(DE-627)859340082
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	R5-920
illustrated	Not Illustrated
issn	22966870
topic_title	R5-920 Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology biomarkers cancer plan companion diagnostics comprehensive genomic profiling diagnostic tests million european genome molecular diagnostics personalised healthcare public health reimbursement challenges
topic	misc R5-920 misc biomarkers misc cancer plan misc companion diagnostics misc comprehensive genomic profiling misc diagnostic tests misc million european genome misc molecular diagnostics misc personalised healthcare misc public health misc reimbursement challenges misc Medicine (General)
topic_unstemmed	misc R5-920 misc biomarkers misc cancer plan misc companion diagnostics misc comprehensive genomic profiling misc diagnostic tests misc million european genome misc molecular diagnostics misc personalised healthcare misc public health misc reimbursement challenges misc Medicine (General)
topic_browse	misc R5-920 misc biomarkers misc cancer plan misc companion diagnostics misc comprehensive genomic profiling misc diagnostic tests misc million european genome misc molecular diagnostics misc personalised healthcare misc public health misc reimbursement challenges misc Medicine (General)
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Biomedicine Hub
hierarchy_parent_id	859340082
hierarchy_top_title	Biomedicine Hub
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)859340082 (DE-600)2855840-6
title	Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology
ctrlnum	(DE-627)DOAJ008577161 (DE-599)DOAJ23c9748ba2f5428dbcd608ea1ef409ad
title_full	Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology
author_sort	Denis Horgan
journal	Biomedicine Hub
journalStr	Biomedicine Hub
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
container_start_page	1
author_browse	Denis Horgan Gennaro Ciliberto Pierfranco Conte David Baldwin Luis Seijo Luis M. Montuenga Luis Paz-Ares Marina Garassino Frederique Penault-Llorca Fabrizia Galli Isabelle Ray-Coquard Denis Querleu Ettore Capoluongo Susana Banerjee Peter Riegman Keith Kerr Benjamin Horbach Reinhard Büttner Hein Van Poppel Anders Bjartell Giovanni Codacci-Pisanelli Benedikt Westphalen Fabien Calvo Jasmina Koeva-Balabanova Stephen Hall Angelo Paradiso Dipak Kalra Christa Cobbaert Rocio Varea Menendez Zorana Maravic Vassiliki Fotaki Jaafar Bennouna Estelle Cauchin Nuria Malats Iñaki Gutiérrez-Ibarluzea Benjamin Gannon Ken Mastris Chiara Bernini William Gallagher Simonetta Buglioni Alastair Kent Elisabetta Munzone Ivica Belina Jan Van Meerbeeck Michael Duffy Elżbieta Sarnowska Beata Jagielska Sarah Mee Giuseppe Curigliano
container_volume	5
class	R5-920
format_se	Elektronische Aufsätze
author-letter	Denis Horgan
doi_str_mv	10.1159/000511209
author2-role	verfasserin
title_sort	bringing greater accuracy to europe’s healthcare systems: the unexploited potential of biomarker testing in oncology
callnumber	R5-920
title_auth	Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology
abstract	Rapid and continuing advances in biomarker testing are not being matched by take-up in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. This paper sets out the potential of biomarker testing, the unfolding precision and range of possible diagnosis and prediction, and the many obstacles to adoption. It offers case studies of biomarker testing in breast, ovarian, prostate, lung, thyroid and colon cancers, and derives specific lessons as to the potential and actual use of each of them. It also draws lessons about how to improve access and alignment, and to remedy the data deficiencies that impede development. And it suggests solutions to outstanding issues – notably including funding and the tangled web of obtaining reimbursement or equivalent coverage that Europe’s fragmented health system implies. It urges a European evolution towards an initial minimum testing scenario, which would guarantee universal access to a suite of biomarker tests for the currently most common conditions, and, further into the future, to an optimum testing scenario in which a much wider range of biomarker tests would be introduced and become part of a more sophisticated health system articulated around personalised medicine. For exploiting genomics to the full, it argues the need for a new policy framework for Europe. Biomarker testing is not an issue that can be treated in isolation, since the purpose of testing is to improve health. Its use is therefore always closely linked to specific health challenges and needs to be viewed in the broader policy context in the EU and more widely. The paper is the result of extensive engagement with experts and decision makers to develop the framework, and consequently represents a wide consensus of views on how healthcare systems should respond from push and pull factors at local, national and cross-border and EU level. It contains strong views and clear recommendations springing from the convictions of patients, clinicians, academics, medicines authorities, HTA bodies, payers, the diagnostic, pharmaceutical and ICT industries, and national policy makers.
abstractGer	Rapid and continuing advances in biomarker testing are not being matched by take-up in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. This paper sets out the potential of biomarker testing, the unfolding precision and range of possible diagnosis and prediction, and the many obstacles to adoption. It offers case studies of biomarker testing in breast, ovarian, prostate, lung, thyroid and colon cancers, and derives specific lessons as to the potential and actual use of each of them. It also draws lessons about how to improve access and alignment, and to remedy the data deficiencies that impede development. And it suggests solutions to outstanding issues – notably including funding and the tangled web of obtaining reimbursement or equivalent coverage that Europe’s fragmented health system implies. It urges a European evolution towards an initial minimum testing scenario, which would guarantee universal access to a suite of biomarker tests for the currently most common conditions, and, further into the future, to an optimum testing scenario in which a much wider range of biomarker tests would be introduced and become part of a more sophisticated health system articulated around personalised medicine. For exploiting genomics to the full, it argues the need for a new policy framework for Europe. Biomarker testing is not an issue that can be treated in isolation, since the purpose of testing is to improve health. Its use is therefore always closely linked to specific health challenges and needs to be viewed in the broader policy context in the EU and more widely. The paper is the result of extensive engagement with experts and decision makers to develop the framework, and consequently represents a wide consensus of views on how healthcare systems should respond from push and pull factors at local, national and cross-border and EU level. It contains strong views and clear recommendations springing from the convictions of patients, clinicians, academics, medicines authorities, HTA bodies, payers, the diagnostic, pharmaceutical and ICT industries, and national policy makers.
abstract_unstemmed	Rapid and continuing advances in biomarker testing are not being matched by take-up in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. This paper sets out the potential of biomarker testing, the unfolding precision and range of possible diagnosis and prediction, and the many obstacles to adoption. It offers case studies of biomarker testing in breast, ovarian, prostate, lung, thyroid and colon cancers, and derives specific lessons as to the potential and actual use of each of them. It also draws lessons about how to improve access and alignment, and to remedy the data deficiencies that impede development. And it suggests solutions to outstanding issues – notably including funding and the tangled web of obtaining reimbursement or equivalent coverage that Europe’s fragmented health system implies. It urges a European evolution towards an initial minimum testing scenario, which would guarantee universal access to a suite of biomarker tests for the currently most common conditions, and, further into the future, to an optimum testing scenario in which a much wider range of biomarker tests would be introduced and become part of a more sophisticated health system articulated around personalised medicine. For exploiting genomics to the full, it argues the need for a new policy framework for Europe. Biomarker testing is not an issue that can be treated in isolation, since the purpose of testing is to improve health. Its use is therefore always closely linked to specific health challenges and needs to be viewed in the broader policy context in the EU and more widely. The paper is the result of extensive engagement with experts and decision makers to develop the framework, and consequently represents a wide consensus of views on how healthcare systems should respond from push and pull factors at local, national and cross-border and EU level. It contains strong views and clear recommendations springing from the convictions of patients, clinicians, academics, medicines authorities, HTA bodies, payers, the diagnostic, pharmaceutical and ICT industries, and national policy makers.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2018 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	3
title_short	Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology
url	https://doi.org/10.1159/000511209 https://doaj.org/article/23c9748ba2f5428dbcd608ea1ef409ad https://www.karger.com/Article/FullText/511209 https://doaj.org/toc/2296-6870
remote_bool	true
author2	Gennaro Ciliberto Pierfranco Conte David Baldwin Luis Seijo Luis M. Montuenga Luis Paz-Ares Marina Garassino Frederique Penault-Llorca Fabrizia Galli Isabelle Ray-Coquard Denis Querleu Ettore Capoluongo Susana Banerjee Peter Riegman Keith Kerr Benjamin Horbach Reinhard Büttner Hein Van Poppel Anders Bjartell Giovanni Codacci-Pisanelli Benedikt Westphalen Fabien Calvo Jasmina Koeva-Balabanova Stephen Hall Angelo Paradiso Dipak Kalra Christa Cobbaert Rocio Varea Menendez Zorana Maravic Vassiliki Fotaki Jaafar Bennouna Estelle Cauchin Nuria Malats Iñaki Gutiérrez-Ibarluzea Benjamin Gannon Ken Mastris Chiara Bernini William Gallagher Simonetta Buglioni Alastair Kent Elisabetta Munzone Ivica Belina Jan Van Meerbeeck Michael Duffy Elżbieta Sarnowska Beata Jagielska Sarah Mee Giuseppe Curigliano
author2Str	Gennaro Ciliberto Pierfranco Conte David Baldwin Luis Seijo Luis M. Montuenga Luis Paz-Ares Marina Garassino Frederique Penault-Llorca Fabrizia Galli Isabelle Ray-Coquard Denis Querleu Ettore Capoluongo Susana Banerjee Peter Riegman Keith Kerr Benjamin Horbach Reinhard Büttner Hein Van Poppel Anders Bjartell Giovanni Codacci-Pisanelli Benedikt Westphalen Fabien Calvo Jasmina Koeva-Balabanova Stephen Hall Angelo Paradiso Dipak Kalra Christa Cobbaert Rocio Varea Menendez Zorana Maravic Vassiliki Fotaki Jaafar Bennouna Estelle Cauchin Nuria Malats Iñaki Gutiérrez-Ibarluzea Benjamin Gannon Ken Mastris Chiara Bernini William Gallagher Simonetta Buglioni Alastair Kent Elisabetta Munzone Ivica Belina Jan Van Meerbeeck Michael Duffy Elżbieta Sarnowska Beata Jagielska Sarah Mee Giuseppe Curigliano
ppnlink	859340082
callnumber-subject	R - General Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1159/000511209
callnumber-a	R5-920
up_date	2024-07-03T18:49:46.699Z
_version_	1803584889633636352
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ008577161</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310012159.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1159/000511209</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ008577161</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ23c9748ba2f5428dbcd608ea1ef409ad</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Denis Horgan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Rapid and continuing advances in biomarker testing are not being matched by take-up in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. This paper sets out the potential of biomarker testing, the unfolding precision and range of possible diagnosis and prediction, and the many obstacles to adoption. It offers case studies of biomarker testing in breast, ovarian, prostate, lung, thyroid and colon cancers, and derives specific lessons as to the potential and actual use of each of them. It also draws lessons about how to improve access and alignment, and to remedy the data deficiencies that impede development. And it suggests solutions to outstanding issues – notably including funding and the tangled web of obtaining reimbursement or equivalent coverage that Europe’s fragmented health system implies. It urges a European evolution towards an initial minimum testing scenario, which would guarantee universal access to a suite of biomarker tests for the currently most common conditions, and, further into the future, to an optimum testing scenario in which a much wider range of biomarker tests would be introduced and become part of a more sophisticated health system articulated around personalised medicine. For exploiting genomics to the full, it argues the need for a new policy framework for Europe. Biomarker testing is not an issue that can be treated in isolation, since the purpose of testing is to improve health. Its use is therefore always closely linked to specific health challenges and needs to be viewed in the broader policy context in the EU and more widely. The paper is the result of extensive engagement with experts and decision makers to develop the framework, and consequently represents a wide consensus of views on how healthcare systems should respond from push and pull factors at local, national and cross-border and EU level. It contains strong views and clear recommendations springing from the convictions of patients, clinicians, academics, medicines authorities, HTA bodies, payers, the diagnostic, pharmaceutical and ICT industries, and national policy makers.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">biomarkers</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cancer plan</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">companion diagnostics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">comprehensive genomic profiling</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">diagnostic tests</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">million european genome</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">molecular diagnostics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">personalised healthcare</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">public health</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">reimbursement challenges</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gennaro Ciliberto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pierfranco Conte</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">David Baldwin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luis Seijo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luis M. Montuenga</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luis Paz-Ares</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marina Garassino</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Frederique Penault-Llorca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fabrizia Galli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Isabelle Ray-Coquard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Denis Querleu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ettore Capoluongo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Susana Banerjee</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Peter Riegman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Keith Kerr</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Benjamin Horbach</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Reinhard Büttner</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hein Van Poppel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anders Bjartell</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giovanni Codacci-Pisanelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Benedikt Westphalen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fabien Calvo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jasmina Koeva-Balabanova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stephen Hall</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Angelo Paradiso</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dipak Kalra</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Christa Cobbaert</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rocio Varea Menendez</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zorana Maravic</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vassiliki Fotaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jaafar Bennouna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Estelle Cauchin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nuria Malats</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Iñaki Gutiérrez-Ibarluzea</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Benjamin Gannon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ken Mastris</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chiara Bernini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">William Gallagher</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Simonetta Buglioni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alastair Kent</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elisabetta Munzone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ivica Belina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jan Van Meerbeeck</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michael Duffy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elżbieta Sarnowska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Beata Jagielska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sarah Mee</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giuseppe Curigliano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Biomedicine Hub</subfield><subfield code="d">Karger Publishers, 2017</subfield><subfield code="g">5(2020), 3, Seite 1</subfield><subfield code="w">(DE-627)859340082</subfield><subfield code="w">(DE-600)2855840-6</subfield><subfield code="x">22966870</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:5</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:1</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1159/000511209</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/23c9748ba2f5428dbcd608ea1ef409ad</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.karger.com/Article/FullText/511209</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2296-6870</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2018</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">5</subfield><subfield code="j">2020</subfield><subfield code="e">3</subfield><subfield code="h">1</subfield></datafield></record></collection>
score	7.40075

Nicht das Richtige dabei?

Schreiben Sie uns!

Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?